Halberd (Halberd) FCF Yield % : -103.88 (As of May. 22, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Halberd FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Halberd's Trailing 12-Month Free Cash Flow is $-0.24 Mil, and Market Cap is $0.23 Mil. Therefore, Halberd's FCF Yield % for today is -103.88%.

The historical rank and industry rank for Halberd's FCF Yield % or its related term are showing as below:

HALB' s FCF Yield % Range Over the Past 10 Years
Min: -211.4 Med: 0 Max: 0
Current: -103.88

HALB's FCF Yield % is ranked worse than
86.12% of 1556 companies
in the Biotechnology industry
Industry Median: -14.16 vs HALB: -103.88

Halberd's FCF Margin % for the quarter that ended in Jul. 2023 was -8,033.33%.

Halberd FCF Yield % Historical Data

The historical data trend for Halberd's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd FCF Yield % Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

FCF Yield %

-14.43

-4.63

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
FCF Yield %	-	-14.43	-4.63

Competitive Comparison of Halberd's FCF Yield %

For the Biotechnology subindustry, Halberd's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Halberd's FCF Yield % falls into.

Halberd FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Halberd's FCF Yield % for the fiscal year that ended in Jul. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-0.241	/	5.2099476
	=	-4.63%

Halberd's annualized FCF Yield % for the quarter that ended in Jul. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-0.241	*	1	/	5.2099476
	=	-4.63%

Halberd FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Halberd FCF Yield % Related Terms

Thank you for viewing the detailed overview of Halberd's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236